Baxter’s Hemopatch Sealing Hemostat Gains Popularity in Australia, New Zealand

Baxter Healthcare has reported a surge in the adoption of its room temperature storage configuration for the Hemopatch Sealing Hemostat across Australia and New Zealand. Launched in the summer of 2025, the product has quickly gained traction among surgical teams, who appreciate its convenience, versatility, and clinical effectiveness.

The Hemopatch Sealing Hemostat is an absorbable collagen pad specifically designed for tissue sealing and hemostasis. Its new room temperature format eliminates the need for refrigeration, significantly simplifying preparation and storage in operating rooms. This innovation has proven especially valuable for managing mild to moderate bleeding scenarios.

Positive Feedback from Surgical Teams

Surgeons in the region have expressed strong support for the product. A/Prof Matthew Roberts, a urological surgeon from Queensland, Australia, remarked, “Hemopatch Sealing Hemostat is an excellent product that is quite versatile across many urological operations. The ability to handle venous bleeding across wide surfaces is great for patients and has allowed me to confidently use Hemopatch Sealing Hemostat.”

Baxter Healthcare emphasizes its commitment to providing meaningful solutions for clinicians. The positive reception of Hemopatch Sealing Hemostat highlights the company’s dedication to enhancing patient outcomes and supporting surgical teams in their efforts.

With a shelf life of up to 36 months and compatibility with both open and minimally invasive procedures, the Hemopatch Sealing Hemostat continues to be a trusted resource in operating rooms across these countries. This device represents a significant advancement in surgical practices, aiming to improve efficiency and patient safety.

Looking Ahead

As healthcare professionals seek innovative tools to enhance surgical procedures, Baxter Healthcare remains focused on delivering products that meet these needs. The success of the Hemopatch Sealing Hemostat in Australia and New Zealand underscores the importance of ongoing innovation in the healthcare sector.

For further details regarding the Hemopatch Sealing Hemostat, healthcare professionals can visit Baxter’s official website or contact local sales representatives for information on availability and regulatory status in their respective countries. Baxter Healthcare, headquartered in Glattbrugg, Switzerland, is committed to developing solutions that save and sustain lives.